Targeting protein translation with omacetaxine mepesuccinate (homoharringtonine) may enhance treatment efficacy in SCLC, opening a new avenue for combinatorial therapy with EZH2 inhibitors. The gene discussed is EZH2; the disease is small cell lung carcinoma.